ORLANDO – A fixed-dose combination of sitagliptin/metformin (Janumet) is superior to pioglitazone( Actos) monotherapy for glucose-lowering in patients with type 2 diabetes, researchers announced here at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA). Investigators compared the efficacy and safety of initial therapy with a fixed-dose combination of sitagliptin plus metformin versus pioglitazone in 517 patients with type 2 diabetes and inadequate glycemic control through diet and exercise…

Credits to:Health News from Medical News Today

Related Posts

• Obese Type 2 Diabetes Patients Have Long-Term Benefits From Intensive Lifestyle Intervention
  If obese/overweight patients with diabetes Type 2 are helped to get fit, lose weight and control blood glucose levels, their long-term outlook improve...
• Diabetics Need Better Grasp Of Hypoglycemia
  New results show significant knowledge deficits among European patients with type 2 diabetes. The data are from the 2010 Exploring Hypoglycemia Surve...
• Testing for Type 2
  An article published in last week's Circulation Journal provides some insight into the possibility of testing people who are going to develop type 2 d...
• Type 2 Diabetes Linked to Alzheimer’s Disease
  The research just keeps piling up -- more and more scientists are reporting a possible link between type 2 diabetes and Alzheimer's Disease (and simil...
• Panel Turns Down FDA Proposal To Control Prescription Narcotic Painkillers
  An FDA (Food and Drug Administration), USA Advisory Committee voted 25 to 10 against a proposal to reduce the abuse and misuse of long-acting narcotic...